Fracture News and Research

RSS

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

FDA approves Prolia for postmenopausal women with osteoporosis

The U.S. Food and Drug Administration approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures.

2 Jun 2010

Hebrew Union College honors Dr. Dean Lorich with 2010 Roger E. Joseph Prize for humanitarian efforts

Dr. Dean Lorich was honored with the 2010 Roger E. Joseph Prize by Hebrew Union College for his humanitarian efforts in treating victims of the recent Haiti earthquake and in Landstuhl, Germany treating soldiers injured in Iraq and in Afghanistan. The award recognizes individuals making lasting contributions to the causes of human rights.

29 May 2010

Amgen announces European approval of Prolia

Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

28 May 2010

$Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy$

Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy

GTx, Inc. today announced that additional study results from the Phase III clinical trial evaluating toremifene 80 mg for the prevention of fractures in men with prostate cancer on androgen deprivation therapy will be presented at the 2010 Annual Meeting of the American Urological Association being held in San Francisco May 29-June 3.

27 May 2010

Dosage of statin drugs given to patients with heart disease should be monitored: Study

The type and dosage of statin drugs given to patients to treat heart disease should be proactively monitored as they can have unintended adverse effects, concludes a new study published on bmj.com.

27 May 2010

6-month results of NovoStent's SAMBA trial for atherosclerotic disease in SFA and popliteal arteries

NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.

26 May 2010

ACOEM publishes new medical treatment guidelines for hip and groin disorders

The American College of Occupational and Environmental Medicine today published new medical treatment guidelines for providing care to workers with injuries and disorders of the hip and groin. The new guidelines, which represent the latest chapter in ACOEM's comprehensive publication Occupational Medicine Practice Guidelines, are available on line now via ACOEM's APG-I web application; a print version will be available in the fall of 2010, when the Third Edition hard-copy of Occupational Medicine Practice Guidelines is published.

26 May 2010

$FDA warns on possible fracture risk with proton pump inhibitors use$

FDA warns on possible fracture risk with proton pump inhibitors use

The U.S. Food and Drug Administration today warned consumers and health care professionals about a possible increased risk of fractures of the hip, wrist, and spine with high doses or long-term use of a class of medications called proton pump inhibitors. The product labeling will be changed to describe this possible increased risk.

26 May 2010

New data from MVP trial on ICDs shows health care use burden

Medtronic, Inc. today released new data from the MVP trial that implantable defibrillator patients receiving anti-tachycardia pacing were less likely to have health care utilization after treatment as compared to those receiving shock therapy.

17 May 2010

Blood flow restriction combined with resistance exercise can increase muscle-mass in older men

For years, researchers have known that resistance exercise training -such as weightlifting, in which muscles work against gravity or another force - can be one of the most effective ways to fight the debilitating muscle loss caused by aging.

15 May 2010

SANUWAVE Health reports $3.0 million net loss for first-quarter 2010

SANUWAVE Health, Inc.,, an emerging medical technology company focused on regenerative medicine, today reported financial results for the three months ended March 31, 2010 and provided a business update.

14 May 2010

Osteoporosis screening of women increased from 34% in 2001 to 64% in 2006: AHRQ

The proportion of women age 65 and over on Medicare who said that they had been screened for osteoporosis increased from 34 percent in 2001 to 64 percent in 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

14 May 2010

$High dose Vitamin D linked to high rate of fractures and falls$

High dose Vitamin D linked to high rate of fractures and falls

Many women have been regularly taking vitamin D supplements in the hope that it is good for their bones. However a new study has shown that high doses of this vitamin can actually increase the number of falls and fractures in older women.

12 May 2010

$Study shows high-dose vitamin D therapy may increase risk of fracture in elderly women$

Study shows high-dose vitamin D therapy may increase risk of fracture in elderly women

Women age 70 years or older who received a single annual high dose of vitamin D had a higher rate of falls and fractures compared to women who received placebo, according to a study in the May 12 issue of JAMA.

12 May 2010

$Proton pump inhibitor use associated with fracture risk in postmenopausal women$

Proton pump inhibitor use associated with fracture risk in postmenopausal women

Proton pump inhibitors, medications that suppress acid in the stomach, appear to be associated with fractures in postmenopausal women and bacterial infections in many patients, and higher doses do not appear any more beneficial for treating bleeding ulcers, according to a series of reports in the May 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

11 May 2010

Winners of IOF-Servier Young Investigator Research Grant

The International Osteoporosis Foundation (IOF) has awarded the IOF-Servier Young Investigator Research Grant to co-winners Dr. Frank DeVries, University of Utrecht, the Netherlands, and Dr. Davide Ruffoni, Institute for Biomechanics, ETH Zurich, Switzerland.

11 May 2010

$IOF: Vitamin D can prevent falls and fractures in older adults$

IOF: Vitamin D can prevent falls and fractures in older adults

The International Osteoporosis Foundation (IOF) has released a new position statement on Vitamin D for older adults which makes important recommendations for vitamin D nutrition from an evidence-based perspective.

11 May 2010

Alphatec Spine reports 25.6% increase in first-quarter 2010 revenue

Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today financial results for the first quarter March 31, 2010.

11 May 2010

$Free online fracture-risk calculator$

Free online fracture-risk calculator

FRAX- is a free online fracture-risk calculator (http://www.shef.ac.uk/FRAX/) that has been developed by the World Health Organization Collaborating Centre for Metabolic Bone Diseases at the University of Sheffield, UK. More and more physicians around the world are using the tool as an aid in making informed treatment decisions in the course of a clinical assessment of their patients.

10 May 2010